We are Finkhoz Roboadvisory Services Private Limited, based in Gurgaon, Haryana, and we provide research and recommendation services, including security baskets. Disclaimer: Research and recommendations are provided without any warranty on performance or returns, and the company is not liable for any losses arising fro ... Read more
Trade Ideas
224
Opinions
602
Followers
57k
Expertise
Quantitative
Growth
Technical
Index Strategies
Market Commentary
Futures & Options
Technical Analysis
Trade Facts
Total Trades
0
Missed Trades
0
Profit Trades
0
0%
Accuracy
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
CIPLA Limited (CIPLA) rose as much as 3% to a day high of ₹1,435 on November 18, after the US Food and Drug Administration (USFDA) gave a clean chit to its InvaGen plant in New York. The stock traded at ₹1,432.80 at 11:37 AM, up 3.23% from the previous close of ₹1,388. Cipla disclosed the update late on November 17.
The USFDA classified InvaGen’s Hauppauge facility on Long Island as No Action Indicated (NAI), the best possible outcome of an inspection. The inspection took place from October 19 to 22, and the report formally closes an earlier inspection at the site. InvaGen is Cipla’s wholly owned US subsidiary.
A clean inspection removes a regulatory overhang. With NAI status, the plant can keep supplying the US market and support new product approvals without the risk of warning letters or import restrictions. For a company with a large US business, a compliant manufacturing base is essential.
The clearance does not fix the bigger US problem. North America revenue in Q2 was $172 million, up $10 million from the previous quarter but 19% lower than a year ago. A clean plant helps protect existing business, but growth depends on new product launches. Investors will want to see whether Cipla can build a US pipeline strong enough to reverse the yearly decline.
Investors should watch new US product approvals and launches, North America revenue in coming quarters, other pending USFDA inspections, and India business growth. The key question is whether Cipla can turn a clean regulatory record into renewed US growth.
Disclosure: I do not hold any position in Cipla Limited. This post is for informational purposes only and is not investment advice.
0
0
shared an insight ⚡️ 4 hours ago
Fairfax exits IIFL Finance in ₹3,454 crore block deal
IIFL Limited (IIFL) is in focus on November 18 as Fairfax’s investment arm, FIH Mauritius Investments, sells up to 5.65 crore shares, or 13.25% of the company, through a block deal worth about ₹3,454 crore. The floor price is ₹611 per share, a 3.9% discount to Tuesday’s BSE close of ₹636.05.
The deal is expected to settle on November 19, with IIFL Capital Services as the sole bookrunner. The stock had already fallen 2.54% on Tuesday as news of the sale emerged. Fairfax is raising money to fund its planned acquisition of a controlling stake in IDBI Bank, which the Cabinet approved in October.
This sale is about Fairfax’s needs, not IIFL’s business. Fairfax has backed IIFL for over a decade and is exiting to free up capital for a much larger bet on IDBI Bank. The timing also works for IIFL. Just last week, Blackstone agreed to invest ₹5,000 crore at ₹602 per share, so a new anchor investor is stepping in as the old one leaves. Even at the floor price, Fairfax is selling above Blackstone’s entry price.
The short-term risk is supply. Absorbing a 13.25% stake in one session is a large amount of stock for the market to digest, and block deals at a discount often cap prices in the near term. Shareholders also face roughly 20% dilution once Blackstone’s investment and the promoter warrants convert. A long-term backer leaving and fresh equity arriving at the same time can weigh on the stock until both are fully absorbed.
Investors should watch who buys in the block deal, the stock’s reaction around ₹611, the December 4 EGM on the Blackstone deal, and gold loan growth. The key question is whether IIFL’s fundamentals can absorb both Fairfax’s exit and Blackstone’s dilution.
Disclosure: I do not hold any position in IIFL Finance Limited. This post is for informational purposes only and is not investment advice.
1
0
shared an insight ⚡️ 23 hours ago
FirstCry parent jumps 13% as JM Financial sees worst over
FIRSTCRY Limited (FIRSTCRY), the parent of FirstCry, rose as much as 12.95% to an intraday high of ₹178.75 on the NSE on November 17, making it the top BSE midcap gainer. The stock snapped a three-day losing run after JM Financial kept its Buy rating and said the worst is likely behind the company.
In Q2 FY27, revenue grew 14.1% to ₹2,395.8 crore, the fastest growth in six quarters, and the net loss narrowed 75.1% to ₹12.6 crore. The India multi-channel business grew 18.6%, its strongest in eight quarters. JM Financial cut its target to ₹245 from ₹255 and reduced FY27 EBITDA estimates by about 18%, but broadly kept FY28–29 forecasts unchanged.
The core business is accelerating, which is the main positive. Management expects stronger growth and margins from Q3, as festive sales shifted out of Q2 and a warehouse transition at GlobalBees is now complete. JM Financial’s target implies about 55% upside from current levels.
Profitability is still the weak spot. The adjusted EBITDA margin fell to 4.9% from 5.8%, and gross margin dropped to 35.1% from 36.7%. Part of the narrower loss came from lower ESOP costs rather than operating gains. Today’s jump also came on a strong market day, and the stock is still down 39% this year and 47% over the past year. One good session after a long fall does not confirm a turnaround.
Investors should watch gross margin recovery in Q3, GlobalBees’ growth after the transition, and progress towards the company’s goal of doubling revenue in five years. The key question is whether FirstCry can turn faster growth into better margins, not just smaller losses.
Disclosure: I do not hold any position in Brainbees Solutions Limited. This post is for informational purposes only and is not investment advice.
What are the top stock recommendations by Finkhoz Roboadvisory Services?
Finkhoz Roboadvisory Services regularly shares stock views and market analysis on StockGro. Some of the stocks they have recently shared views on include Punjab National Bank (Bullish), CIPLA, IIFL and FIRSTCRY. Explore Finkhoz Roboadvisory Services's complete list of posts and trade views on their StockGro profile.
How can I follow Finkhoz Roboadvisory Services's latest investment insights?
You can follow Finkhoz Roboadvisory Services's latest investment insights, stock recommendations, and market analysis on StockGro App. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is Finkhoz Roboadvisory Services's investment strategy?
Finkhoz Roboadvisory Services follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has Finkhoz Roboadvisory Services been a SEBI-registered Research Analyst (RA)?
Finkhoz Roboadvisory Services has been a SEBI-registered Research Analyst and have 5+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see Finkhoz Roboadvisory Services's past performance and stock picks?
You can check Finkhoz Roboadvisory Services's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact Finkhoz Roboadvisory Services for stock market advice?
For stock market guidance from Finkhoz Roboadvisory Services, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is Finkhoz Roboadvisory Services's track record in predicting market movements?
Finkhoz Roboadvisory Services has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for Finkhoz Roboadvisory Services?
Finkhoz Roboadvisory Services is a SEBI-registered Research Analyst with the SEBI Registration INH000022297. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.